Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Chrysos Corporation Lifts Revenue 27% as PhotonAssay Fleet Grows to 51 Units
Source: Kapitales Research
Highlights:
Unaudited revenue for July to October 2026 reached AU$36.7 million, up 27% on the prior period.
PhotonAssay samples hit 4.91 million, up 43%, with 51 units now deployed worldwide.
FY27 guidance was reaffirmed at AU$108 million to AU$118 million in revenue and AU$35 million to AU$42 million in EBITDA.
Strong Start to FY27
Chrysos Corporation Limited (ASX: C79) told investors on 19 November 2026 that the first four months of FY27 have been strong, helped by high mining and exploration activity. Unaudited revenue for July to October was AU$36.7 million, a 27% rise. Managing director Dirk Treasure presented the update ahead of the company’s annual meeting. Chrysos shares last traded at AU$6.590, up 7.504%.
Record Sample Volumes
The company analysed 4.91 million PhotonAssay samples in the period, 43% more than a year earlier, while the fleet stayed above 90% availability. Monthly volumes have exceeded one million since March 2026, and October alone reached 1.36 million, up 48%. Revenue came from AU$22.6 million of minimum monthly assay payments, up 7%, and AU$13.7 million of additional assay charges, up 79%. Additional charges now make up 38% of PhotonAssay revenue, compared with 26% a year earlier.
Fleet Expansion
Six new units were deployed this financial year and six more are being installed, taking the global fleet to 51 units after one decommissioned unit in Mali. Fifteen lease agreements were signed, lifting contracted units to 97. That already exceeds the company’s target of 90 deployed units by the end of FY29, and manufacturing capacity has been lifted to 18 units a year.
Funding and Guidance
Chrysos reported a funding position of AU$139.5 million, made up of AU$19.5 million in cash and AU$120 million in undrawn debt, and says it is operating cash flow positive. It reaffirmed FY27 guidance for revenue of AU$108 million to AU$118 million and EBITDA of AU$35 million to AU$42 million.
What to Watch Next
Investors will be watching further unit deployments, the conversion of contracted units into installed ones and whether volumes stay above one million samples a month.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Chrysos Corporation Lifts Revenue 27% as PhotonAssay Fleet Grows to 51 Units
Highlights:
Unaudited revenue for July to October 2026 reached AU$36.7 million, up 27% on the prior period.
PhotonAssay samples hit 4.91 million, up 43%, with 51 units now deployed worldwide.
FY27 guidance was reaffirmed at AU$108 million to AU$118 million in revenue and AU$35 million to AU$42 million in EBITDA.
Strong Start to FY27
Chrysos Corporation Limited (ASX: C79) told investors on 19 November 2026 that the first four months of FY27 have been strong, helped by high mining and exploration activity. Unaudited revenue for July to October was AU$36.7 million, a 27% rise. Managing director Dirk Treasure presented the update ahead of the company’s annual meeting. Chrysos shares last traded at AU$6.590, up 7.504%.
Record Sample Volumes
The company analysed 4.91 million PhotonAssay samples in the period, 43% more than a year earlier, while the fleet stayed above 90% availability. Monthly volumes have exceeded one million since March 2026, and October alone reached 1.36 million, up 48%. Revenue came from AU$22.6 million of minimum monthly assay payments, up 7%, and AU$13.7 million of additional assay charges, up 79%. Additional charges now make up 38% of PhotonAssay revenue, compared with 26% a year earlier.
Fleet Expansion
Six new units were deployed this financial year and six more are being installed, taking the global fleet to 51 units after one decommissioned unit in Mali. Fifteen lease agreements were signed, lifting contracted units to 97. That already exceeds the company’s target of 90 deployed units by the end of FY29, and manufacturing capacity has been lifted to 18 units a year.
Funding and Guidance
Chrysos reported a funding position of AU$139.5 million, made up of AU$19.5 million in cash and AU$120 million in undrawn debt, and says it is operating cash flow positive. It reaffirmed FY27 guidance for revenue of AU$108 million to AU$118 million and EBITDA of AU$35 million to AU$42 million.
What to Watch Next
Investors will be watching further unit deployments, the conversion of contracted units into installed ones and whether volumes stay above one million samples a month.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au